Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ella Clear all
Completed Early Phase 1 Interventional

Ulipristal Acetate for Cervical Preparation

NCT03802149
View directory record Official record
Conditions
Termination of Pregnancy
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of CDB-2914 for Emergency Contraception

NCT00411684
View directory record Official record
Conditions
Emergency Contraception
Interventions
CDB-2914
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
17
States / cities
San Jose, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Nov 9, 2026, 1:00 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

NCT01107106
View directory record Official record
Conditions
Contraception
Interventions
ellaOne® (ulipristal acetate)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Lakewood, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Nov 9, 2026, 1:00 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

NCT01569737
View directory record Official record
Conditions
Emergency Contraception
Interventions
ella
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 9, 2026, 1:00 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

NCT03537768
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679
View directory record Official record
Conditions
Focus: Estrogen-free Oral Contraception
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

NCT00041899
View directory record Official record
Conditions
Healthy
Interventions
CDB-2914, COB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 9, 2026, 1:00 AM EST
Completed No phase listed Observational

Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

NCT05285605
View directory record Official record
Conditions
Contraception, Contraceptive Usage, Reproductive Issues
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 9, 2026, 1:00 AM EST
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

NCT01553123
View directory record Official record
Conditions
Leiomyomas
Interventions
Ulipristal Acetate, Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Nov 9, 2026, 1:00 AM EST
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

NCT03296098
View directory record Official record
Conditions
Contraception, Healthy Female
Interventions
Ulipristal acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 9, 2026, 1:00 AM EST
Completed Early Phase 1 Interventional Results available

Ovarian Function With ENG Implant and UPA Use

NCT04291001
View directory record Official record
Conditions
Contraception
Interventions
ENG implant, oral ulipristal acetate
Device · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 9, 2026, 1:00 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

NCT03208985
View directory record Official record
Conditions
Emergency Contraception
Interventions
Use Phase (Ulipristal Acetate, 30 mg)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
34
States / cities
Rancho Cucamonga, California • Boulder, Colorado • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Nov 9, 2026, 1:00 AM EST